Shots:
The (OPTIC) study evaluates ADVM-022 in patients with wet AMD. The results showed a continuous & consistent therapeutic aflibercept expression level from ADVM-022 @3yrs. after a single IVT inj., no patients in 2×1011 vg/eye (2E11) required any topical corticosteroids
80% had baseline NAbs titers of <1:125 against AAV.7m8 & showed robust aflibercept protein expression & required fewer supplemental anti-VEGF inj., 81% reduction in mean annualized anti-VEGF inj. rate in patients with 2E11; 93% in NAbs titers <1:125; 70% in annualized rate of CST fluctuation with NAbs <1:125
In Q3’22, the P-II study in wet AMD will begin with a 2E11 & 6E10 dose of ADVM-022 with preventive steroid regimens
Ref: Globenewswire| Image: Adverum
